GENETIC TECHNOLOGIES LIMITED — Capital/Financing Update 2024

Aug 11, 2024

==> picture [107 x 71] intentionally omitted <==

Genetic Technologies Limited 60-66 Hanover St Fitzroy VIC 3065, Australia www.genetype.com info@genetype.com +613 8412 7000 ABN: 17 009 212 328

ASX Market Announcement

12 August 2024

Dear Shareholder

Ineligible Shareholders – Genetic Technologies Limited Entitlement Offer

On 25 July 2024, Genetic Technologies Limited ACN 009 212 328 ( Company ) announced that it is undertaking a non-renounceable pro-rata entitlement offer of 2 new Share for every 3 Shares held at the Record Date of 7.00pm on 7 August 2024 ( Record Date ), at an Issue Price of $0.004 (4 cents) per new Share ( Entitlement ), plus 1 New Option to purchase 1 Share for every New Share issued under the Offer (collectively, Entitlement Offer ) to raise a minimum of $2 million ( Minimum Subscription Amount ) and up to maximum of approximately $3.88 million (before costs)( Maximum Subscription Amount ), the maximum being on the basis that no more than approximately 96,944,831 New Shares and 96,944,831 New Options will be issued pursuant to the Entitlement Offer.

Shareholders who subscribe for their full Entitlement will also be able to subscribe for Additional Shares at the same price (plus 1 New Option for every Additional Share issued) ( Top-Up Offer ). The Company will not apply to list the New Options on the ASX.

The Directors have reserved the right for up to 3 months after the close of the Entitlement Offers to place any shortfall under the Entitlement Offers (if any) ( Shortfall ) at a price no less than the Issue Price ( Shortfall Offer ).

The Entitlement Offer, Top-Up Offer and Shortfall Offers are being made pursuant to a prospectus dated 2 August 2024 issued in accordance Section 713 of the Corporations Act ( Offers Prospectus ). A copy of the above announcement, together with further details of the Offers, are available on the Company's website www.genetype.com/investor-centre and on the ASX Announcement Platform. A copy of the Offers Prospectus has been lodged with the Australian Securities and Investments Commission ( ASIC ) and the ASX and is available for viewing on the ASIC website, the ASX website and the Company's website.

Restrictions apply upon eligibility to participate in the Entitlement Offer. As permitted by law, the Company has decided, pursuant to ASX Listing Rule 7.7.1(a) and section 9A(3)(a) of the Corporations Act, that it is unreasonable to make the Entitlement Offer to any Shareholder with a registered address outside Australia or New Zealand (retail and wholesale shareholders) as at the Record Date (namely 7 August 2024), having regard to:

• (a) the relatively small number of Shareholders with addresses in such other countries as a proportion of total Shareholders in the Company;

1

• (b) the relatively small number and value of the Shares those Shareholders would be offered under the Entitlement Offer; and

• (c) the cost to the Company of complying with applicable legal and regulatory requirements in such other countries.

Accordingly, the Entitlement Offer (including the Top-Up Offer) will not be made to shareholders resident in the jurisdiction in which your shareholding is registered.

This letter is to inform you that according to our records, under the terms of the Entitlement Offer you are an ineligible shareholder and therefore not eligible to subscribe for new Shares (and New Options) and no Entitlements will be issued to you. Accordingly, the Company is not extending the Entitlement Offer and Top-Up Offer to you and this letter is not an offer to issue New Shares or Entitlements to you, nor an invitation for you to applyfor new Shares (and New Options).

You are not required to do anything in response to this letter.

If you have any questions, please contact the Company via the Offer Information Line on (03) 8412 7000 (within Australia) or +613 8412 7000 (outside Australia) or via email at investors@genetype.com.

For other questions, you should contact your stockbroker, accountant, taxation advisor, financial advisor or other professional advisor.

Yours faithfully,

==> picture [93 x 63] intentionally omitted <==

Mark Ziirsen

Company Secretary

2